ClinicalTrials.gg
CompletedNCT01772368Updated Jun 12, 2017Results posted

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

A Phase 2 interventional study of Fp MDPI and FS MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 10 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-06-12.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
80th of 146
72 · median 100
Started
2013
with 7 others
Phase 2
25 of 147
none open now
Registered
97th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 80th largest by enrollment of the 146 interventional ones that give a count, is one of 8 that started in 2013, is one of 25 in phase 2, and was the 97th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100 mcg) delivered as Fluticasone/Salmeterol Spiromax® Inhalation Powder (FS Spiromax) when administered as a single dose in subjects 12 years of age and older with persistent asthma.

Read the detailed description

This was a multicenter, randomized, double-blind and open-label active-controlled, single-dose, 6 period crossover, dose-ranging study conducted in male and female subjects ages 12 years and older with persistent asthma.

Fluticasone propionate multidose dry powder inhaler (Fp MDPI) 50 mcg was provided (to replace the subject's current inhaled corticosteroid (ICS)) throughout the 14 day run-in period and each of the washout periods between treatments. Subjects were instructed to administer 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily during the run-in and washout periods. All other medications for the treatment of asthma were discontinued at or prior to the screening visit.

A short-acting β2-adrenergic agonist (SABA), salbuterol HFA, MDI, was provided (to replace the subject's current rescue medication) for symptomatic relief of asthma symptoms in each the run-in, treatment, and washout periods.

Treatment period lasted 5 weeks with a 5 to 7 day washout between each of the six single dose treatments:

  • fluticasone propionate/salmeterol xinafoate multidose dry powder inhaler (FS MDPI) given in doses of 6.25, 12.5, 25, or 50 mcg of salmeterol xinafoate in blinded fashion.
  • fluticasone propionate multidose dry powder inhaler (Fp MDPI) 100 mcg in blinded fashion
  • ADVAIR DISKUS, 100/50 mcg in open-label fashion
03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • dry powder inhaler
  • long-acting beta2-agonist
  • bronchodilation
  • bronchodilator
  • metered dose inhaler
  • inhaled corticosteroid
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written /assent
  • General good health
  • Diagnosis of asthma as defined by the National Institutes of Health (NIH)
  • A best of 40%-85% of the predicted normal value during the screening visit (SV)
  • Subjects need to demonstrate a ≥ 15% reversibility of FEV1 within 30 minutes following 4 inhalations of albuterol inhalation aerosol (if required, spacers are permitted for reversibility testing) at the SV.
  • Other inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • History of life-threatening asthma that is defined for this protocol as an asthma episode that required intubation.
  • Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks prior to the SV.
  • Any asthma exacerbation requiring oral within 3 months of the SV. A subject must not have had any hospitalization for asthma within 6 months prior to the SV.
  • Taking long-acting β-agonists within 2 weeks of the SV
  • Other exclusion criteria apply.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
72 participants (actual)

Study arms

  • Experimental
    FS MDPI 100/6.25 mcg

    Subjects inhaled a single dose of 100 mcg fluticasone propionate and 6.25 mcg salmeterol xinafoate.

    Drug: FS MDPI · Drug: Albuterol

  • Experimental
    FS MDPI 100/12.5mcg

    Subjects inhaled a single dose of 100 mcg fluticasone propionate and 12.5 mcg salmeterol xinafoate.

    Drug: FS MDPI · Drug: Albuterol

  • Experimental
    FS MDPI 100/25

    Subjects inhaled a single dose of 100 mcg fluticasone propionate and 25 mcg salmeterol xinafoate.

    Drug: FS MDPI · Drug: Albuterol

  • Experimental
    FS MDPI 100/50

    Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate.

    Drug: FS MDPI · Drug: Albuterol

  • Active comparator
    Fp MDPI 100 mcg

    Subjects inhaled a single dose of 100 mcg fluticasone propionate.

    Drug: Fp MDPI · Drug: Albuterol

  • Active comparator
    Advair Diskus 100/50 mcg

    Subjects inhaled a single dose of 100 mcg fluticasone propionate and 50 mcg salmeterol xinafoate. This arm is the only arm which is open-label because the inhaler device was different than the MDPI used in the other treatment arms.

    Drug: Advair Diskus · Drug: Albuterol

Interventions

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments.

    Also known as: fluticasone propionate, inhaled corticosteroid, Fp Spiromax

  • FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.

    Also known as: fluticasone propionate, inhaled corticosteroid, Salmeterol xinafoate, β2 adrenoceptor agonist, FS Spiromax

  • DrugAdvair Diskus

    ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.

    Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist

  • Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).

    Also known as: Pro-Air, short-acting β2-adrenergic agonists

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)

    Standardized baseline-adjusted FEV1 AUC0-12 was defined as the area under the curve for baseline-adjusted FEV1 measurements from the predose to 12 hours postdose time points using the trapezoidal rule based on actual (not scheduled) time of measurement and was standardized by dividing the actual time of last non-missing FEV1 measurement. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting period-specific baseline FEV1. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.

    Time frame: Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours

Secondary outcomes

  1. Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment

    The secondary efficacy variable was the change from period-specific baseline in FEV1 at 12 hours, calculated as FEV1 measured at 12 hours postdose after subtracting period-specific baseline FEV1 at each treatment period. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.

    Time frame: Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 12 hours

  2. Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol

    Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.

    Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose

  3. Maximum Observed Plasma Concentration (Cmax) of Salmeterol

    Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.

    Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose

  4. Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol

    Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived.

    Time frame: Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose

  5. Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    TEAEs were recorded during each double-blind treatment. In addition, at the end of each treatment, patients continued to use 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily, so adverse events during this treatment were assigned to Fp MDPI 50 mcg. An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical in

    Time frame: Day 1 up to Day 35

07

Results

Posted Apr 12, 2017

Participant flow

A total of 105 subjects with asthma were screened for this study. Of the 105 subjects screened, 82 subjects at 10 investigational sites in the US met entry criteria and were considered to be eligible to enter the run-in period.

Participant flow — Overall Study
MilestoneAll Participants
Started72
Received fp mdpi 100 mcg67
Received fs mdpi 100/6.25 mcg68
Received fs mdpi 100/12.5mcg69
Received fs mdpi 100/25 mcg67
Received fs mdpi 100/50 mcg68
Received advair diskus 100/50 mcg66
Completed65
Not completed7
Withdrew: Adverse event1
Withdrew: Withdrawal by subject3
Withdrew: Protocol violation2
Withdrew: Other1

Outcome measures

PrimaryStandardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)

Standardized baseline-adjusted FEV1 AUC0-12 was defined as the area under the curve for baseline-adjusted FEV1 measurements from the predose to 12 hours postdose time points using the trapezoidal rule based on actual (not scheduled) time of measurement and was standardized by dividing the actual time of last non-missing FEV1 measurement. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting period-specific baseline FEV1. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.

Time frame:
Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 0.5, 1, 2, 3, 4, 5, 6, 9, 12 hours
Reported as:
Least squares mean · mL
Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)
mLFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcg
Standardized Baseline-Adjusted Area Under the Curve For Forced Expiratory Volume In 1 Second Over 12 Hours Post-dose (FEV1 AUC0-12)52.13 ± 38.071203.84 ± 38.072248.98 ± 38.025279.69 ± 38.121303.43 ± 38.062245.56 ± 38.148
Statistical analysis
  • Fp MDPI 100 mcg vs FS MDPI 100/6.25 mcg vs FS MDPI 100/12.5mcg vs FS MDPI 100/25 mcg vs FS MDPI 100/50 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.)Fixed effects of sequence, period and treatment; a random effect of subject within sequence; and a covariate of period-specific baseline FEV1.
  • Fp MDPI 100 mcg vs FS MDPI 100/50 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 251.30 · 95% CI 215.6 to 287.1FS MDPI 100/50 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/25 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 227.56 · 95% CI 191.6 to 263.5FS MDPI 100/25 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/12.5mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 196.85 · 95% CI 161.2 to 232.5FS MDPI 100/12.5 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/6.25 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 151.71 · 95% CI 115.9 to 187.5FS MDPI 100/6.25 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 193.42 · 95% CI 157.4 to 229.5Advair Diskus 100/50 mcg - Fp MDPI 100
  • FS MDPI 100/50 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.0017 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 57.88 · 95% CI 22.0 to 93.7FS MDPI 100/50 - Advair Diskus 100/50 mcg
  • FS MDPI 100/25 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.0624 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 34.14 · 95% CI -1.8 to 70.1FS MDPI 100/25 mcg - Advair Diskus 100/50 mcg
  • FS MDPI 100/12.5mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.8503 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: 3.42 · 95% CI -32.3 to 39.1FS MDPI 100/12.5mcg - Advair Diskus 100/50 mcg
  • FS MDPI 100/6.25 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.0229 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: -41.72 · 95% CI -77.6 to -5.8FS MDPI 100/6.25 mcg - Advair Diskus 100/50 mcg
  • Fp MDPI 100 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = <0.0001 (A fixed-sequence testing procedure was employed to control the overall Type I error rate at the 2 sided 0.05 level.) · Lsm difference: -193.42 · 95% CI -229.5 to -157.4Fp MDPI 100 mcg - Advair Diskus 100/50 mcg
SecondaryChange From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment

The secondary efficacy variable was the change from period-specific baseline in FEV1 at 12 hours, calculated as FEV1 measured at 12 hours postdose after subtracting period-specific baseline FEV1 at each treatment period. The period-specific baseline FEV1 was measured at predose within 5 minutes of AM dose administration at each treatment visit. If that value was missing, then FEV1 measured at 30 minutes predose was used as the period-specific baseline.

Time frame:
Pre-dose: 30 minutes prior, within 5 minutes of dose. Post-dose: 12 hours
Reported as:
Least squares mean · mL
Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment
mLFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcg
Change From Baseline at 12 Hours Post-Dose in Forced Expiratory Volume in One Second (FEV1) By Treatment11.53 ± 29.058128.49 ± 29.109170.51 ± 28.990209.85 ± 29.127238.30 ± 28.988170.54 ± 29.230
Statistical analysis
  • Fp MDPI 100 mcg vs FS MDPI 100/50 mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 226.77 · 95% CI 172.4 to 281.1FS MDPI 100/50 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/25 mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 198.32 · 95% CI 143.7 to 252.9FS MDPI 100/25 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/12.5mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 158.99 · 95% CI 104.7 to 213.3FS MDPI 100/12.5 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs FS MDPI 100/6.25 mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 116.96 · 95% CI 62.4 to 171.6FS MDPI 100/6.25 mcg - Fp MDPI 100 mcg
  • Fp MDPI 100 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 159.01 · 95% CI 104.3 to 213.7Advair Diskus 100/50 mcg - Fp MDPI 100 mcg
  • FS MDPI 100/50 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.0150 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 67.76 · 95% CI 13.3 to 122.2FS MDPI 100/50 mcg - Advair Diskus 100/50 mcg
  • FS MDPI 100/25 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.1578 (significance of 0.05 or alpha of 0.05.) · Lsm difference: 39.31 · 95% CI -15.3 to 94.0FS MDPI 100/25 mcg - Advair Diskus 100/50 mcg
  • FS MDPI 100/12.5mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.9993 (significance of 0.05 or alpha of 0.05.) · Lsm difference: -0.02 · 95% CI -54.4 to 54.4FS MDPI 100/12.5 mcg - Advair Diskus 100/50 mcg
  • FS MDPI 100/6.25 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = 0.1311 (significance of 0.05 or alpha of 0.05.) · Lsm difference: -42.05 · 95% CI -96.7 to 12.6FS MDPI 100/6.25 mcg - Advair Diskus 100/50 mcg
  • Fp MDPI 100 mcg vs Advair Diskus 100/50 mcg · ANCOVA · p = <0.0001 (significance of 0.05 or alpha of 0.05.) · Lsm difference: -159.01 · 95% CI -213.7 to -104.3Fp MDPI 100 mcg - Advair Diskus 100/50 mcg
SecondaryArea Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol

Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.

Time frame:
Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Reported as:
Mean · pg*hr/mL
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol
pg*hr/mLFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcg
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Measurable Concentration (AUC0-t) of Salmeterol—32.8 ± 20.9869.9 ± 35.36133.5 ± 63.13309.3 ± 143.43173.5 ± 106.59
Statistical analysis
  • FS MDPI 100/50 mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 1.929 · 90% CI 1.690 to 2.202
  • FS MDPI 100/25 mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 0.800 · 90% CI 0.702 to 0.911
  • FS MDPI 100/12.5mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 0.427 · 90% CI 0.376 to 0.485
  • FS MDPI 100/6.25 mcg vs Advair Diskus 100/50 mcg · Lsm difference: 0.172 · 90% CI 0.151 to 0.196
SecondaryMaximum Observed Plasma Concentration (Cmax) of Salmeterol

Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived. The primary pharmacokinetic parameters were AUC0-t and Cmax for Salmeterol.

Time frame:
Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Reported as:
Mean · pg/mL
Maximum Observed Plasma Concentration (Cmax) of Salmeterol
pg/mLFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcg
Maximum Observed Plasma Concentration (Cmax) of Salmeterol—16.0 ± 8.8635.8 ± 20.2567.5 ± 34.71154.5 ± 80.2842.3 ± 19.28
Statistical analysis
  • FS MDPI 100/50 mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 3.622 · 90% CI 3.149 to 4.168
  • FS MDPI 100/25 mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 1.534 · 90% CI 1.335 to 1.763
  • FS MDPI 100/12.5mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 0.795 · 90% CI 0.694 to 0.911
  • FS MDPI 100/6.25 mcg vs Advair Diskus 100/50 mcg · Geometric mean ratio: 0.339 · 90% CI 0.295 to 0.390
SecondaryTime of Maximum Observed Plasma Concentration (Tmax) of Salmeterol

Blood samples for measurement of plasma SAL concentrations were obtained during each treatment visit (subjects 18 years of age and older only) and pharmacokinetic parameters were derived.

Time frame:
Predose (0), and at 5, 10, 15 and 30 minutes, 1, 1.5, 2, 3, 4, 8, and 12 hours postdose
Reported as:
Median · hours
Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol
hoursFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcg
Time of Maximum Observed Plasma Concentration (Tmax) of Salmeterol—0.1 (0.1 to 12.1)0.1 (0.1 to 2.0)0.1 (0.1 to 2.0)0.1 (0.1 to 1.5)0.5 (0.1 to 2.0)
SecondaryPatients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

TEAEs were recorded during each double-blind treatment. In addition, at the end of each treatment, patients continued to use 2 inhalations of Fp MDPI 50 mcg (100 mcg total dose) twice daily, so adverse events during this treatment were assigned to Fp MDPI 50 mcg. An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relationship of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical in

Time frame:
Day 1 up to Day 35
Reported as:
Count of participants · Participants
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
ParticipantsFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcgFp MDPI 50 mcg X 2 BID
Any adverse event22311317
Severe adverse event0000101
Treatment-related adverse event0010011
Deaths0000000
Other serious adverse events0000000
Withdrawn from treatment due to AE0000001

Adverse events

Collected over Day 1 to Day 35. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fp MDPI 100 mcg0/67 (0%)0/67 (0%)0/67 (0%)
FS MDPI 100/6.25 mcg0/68 (0%)0/68 (0%)0/68 (0%)
FS MDPI 100/12.5mcg0/69 (0%)0/69 (0%)0/69 (0%)
FS MDPI 100/25 mcg0/67 (0%)0/67 (0%)0/67 (0%)
FS MDPI 100/50 mcg0/68 (0%)0/68 (0%)0/68 (0%)
Advair Diskus 100/50 mcg0/66 (0%)0/66 (0%)0/66 (0%)
Fp MDPI 50 mcg X 2 BID0/72 (0%)0/72 (0%)4/72 (5.6%)
Most frequent other events
Most frequent other events
EventFp MDPI 100 mcgFS MDPI 100/6.25 mcgFS MDPI 100/12.5mcgFS MDPI 100/25 mcgFS MDPI 100/50 mcgAdvair Diskus 100/50 mcgFp MDPI 50 mcg X 2 BID
Upper respiratory tract infectionRespiratory, thoracic and mediastinal disorders0/670/680/690/670/680/664/72

Baseline characteristics

Intent-to-Treat population

Age, Continuous
Age, Continuous(years)All Participants
Mean42.5 ± 13.87
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female37
Male35
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White64
Black7
Other1
Weight
Weight(kg)All Participants
Mean79.2 ± 14.17
Height
Height(cm)All Participants
Mean170.0 ± 9.76
Body Mass Index
Body Mass Index(kg/m^2)All Participants
Mean27.3 ± 3.35
08

Study locations

10 sites
  • Teva Investigational Site 10453
    Denver, Colorado, United States
  • Teva Investigational Site 10452
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10455
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10454
    Skillman, New Jersey, United States
  • Teva Investigational Site 10448
    Raleigh, North Carolina, United States
  • Teva Investigational Site 10451
    Medford, Oregon, United States
  • Teva Investigational Site 10449
    Portland, Oregon, United States
  • Teva Investigational Site 10457
    El Paso, Texas, United States
  • Teva Investigational Site 10450
    New Braunfels, Texas, United States
  • Teva Investigational Site 10456
    San Antonio, Texas, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 10 months after primary completion. A results delay was requested in Mar 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2013
First posted
Jan 21, 2013
Start
Jan 2013
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results delay requested
Mar 19, 2015
Results first posted
Apr 12, 2017
Last update
Jun 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01772368
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Jan 2013
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Apr 12, 2017
Last update
Jun 12, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion